Oddo Bhf set a €116.00 ($134.88) price target on MorphoSys (ETR:MOR) in a research note published on Monday. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also commented on the company. Commerzbank set a €107.00 ($124.42) price objective on MorphoSys and gave the stock a neutral rating in a research note on Friday. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on MorphoSys and gave the stock a buy rating in a research note on Tuesday, November 13th. Goldman Sachs Group set a €86.00 ($100.00) price objective on MorphoSys and gave the stock a neutral rating in a research note on Tuesday, November 6th. Royal Bank of Canada set a €65.00 ($75.58) price objective on MorphoSys and gave the stock a sell rating in a research note on Friday, November 2nd. Finally, Independent Research set a €105.00 ($122.09) price target on MorphoSys and gave the company a neutral rating in a research note on Thursday, September 27th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of Hold and an average price target of €97.40 ($113.26).

MorphoSys stock opened at €95.75 ($111.34) on Monday. MorphoSys has a one year low of €49.63 ($57.71) and a one year high of €88.10 ($102.44).

About MorphoSys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Read More: What are no-load funds?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.